Precigen Inc

PGEN remains in a Stage 2 advancing structure above the 50-day SMA, but the active Bullish Exhaustion pattern at late-August highs signals waning upside momentum. Price is pulling back into declining 9- and 20-day EMAs with RSI in a neutral range, offering a buy-on-dip setup. Medium-term bias stays bullish, while short-term timing is neutral—entries are best deferred until clear acceptance off the EMA zone.

• ↑Q2 revenue $55M; Papimius sales $53.1M, up 145% QoQ
• ↑FDA approval and 7-year orphan drug exclusivity for RRP therapy
• ↓Insiders sold ~235K shares (~$1.38M), flagging possible concern